A Deacetylase-Deficient SIRT1 Variant Opposes Full-Length SIRT1 in Regulating Tumor Suppressor p53 and Governs Expression of Cancer-Related Genes
A Deacetylase-Deficient SIRT1 Variant Opposes Full-Length SIRT1 in Regulating Tumor Suppressor p53 and Governs Expression of Cancer-Related Genes
Z. Shah,S. Ahmed,3 Authors,J. Milner
2011 · DOI: 10.1128/MCB.06448-11
Molecular and Cellular Biology · 32 Citations
TLDR
The discovery of Sirt1-Δ2/9 identifies a new, deacetylase-independent therapeutic target for SIRT1-related diseases, including cancer.